Public-domain · open source
OpenJurist
← 800 F.2d 1077 - In re Innotron Diagnostics

In re Innotron Diagnostics’s Empirical Analysis

800 F.2d 1077 · 1986

Citation profile

81
cited by 81 later decisions
May 2017
most recently cited

27 federal appellate · 12 district ·

How this case has been cited

Cited by 81 later decisions — most recently May 2017 · most notably Allison v. Citgo Petroleum Corp. (1998), Hoffman v. Merrell Dow Pharmaceuticals, Inc. (1988)

27 federal appellate · 12 district ·

3401986199020002010decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Relationships

Applies 15 U.S.C. § 1 (§ 1 of the Sherman Antitrust Act) · 28 U.S.C. § 1294 · 28 U.S.C. § 1295 · 28 U.S.C. § 1331 · 28 U.S.C. § 1338 · 28 U.S.C. § 1346 (Federal Tort Claims Act) · 28 U.S.C. § 1651 · 28 U.S.C. § 332

Relies on Beacon Theaters Inc v. C Westover · Will v. United States · Roche v. Evaporated Milk Ass'n · Bankers Life & Casualty Co. v. Holland · La Buy v. Howes Leather Co.

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 81 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “'[T]he prohibition is not against having two juries review the same evidence, but rather against having two juries decide the same essential issues.'”
    3 later decisions quote this exact passage
  2. “The district court’s consolidation of the cases produced the same status as that which would have [been] obtained if [the defendant] had filed its patent claim as a counterclaim.... It would, of course, be incongruous to hold that consolidation of a separate suit ... is distinct, in relation to this court’s jurisdiction, from the presence of a counterclaim raising the same allegations of patent infringement that are not “immaterial, inferential, [or] frivolous,” or a “mere joinder.” [Senate Report at 20], Thus, whether allegations of patent infringement be filed and maintained as a viable, non-frivolous counterclaim in a non-patent case, or as a separate complaint which is then consolidated with the non-patent case, the district court’s jurisdiction is based “in part” on § 1338(a) and this court must exercise its exclusive appellate jurisdiction over the entire case. 28 U.S.C. § 1295 (a)(1). Thus the mere labeling and sequencing of pleadings in the trial tribunal cannot be allowed to control every exercise of this court’s appellate jurisdiction.”
    2 later decisions quote this exact passage
  3. ““The court, in furtherance of convenience or to avoid prejudice, or when separate trials will be conducive to expedition and economy, may order a separate trial of any claim, cross-claim, counterclaim, or third-party claim, or of any separate issue or of any number of claims, cross-claims, counterclaims, third-party claims, or issues, always preserving inviolate the right of trial by jury as declared by the Seventh Amendment to the Constitution or as given by a statute of the United States.””
    2 later decisions quote this exact passage

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.